A Phase 3 interventional study of Liraglutide in Brain Death, sponsored by Hospital de Clinicas de Porto Alegre. Completed at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-05.
Sponsored by Hospital de Clinicas de Porto Alegre · Phase 3, Interventional, and Treatment
There is evidence of the association of brain death and inflammation, affecting outcomes of transplanted organs, but in a way not fully understood. Observational studies suggest that the use of target-guided therapies has a beneficial effect in reducing the rate of donor loss due to cardiac arrest and increasing the rate of donor-picked organs, which will be tested through the randomized clinical trial. However, no study so far has directly tested the effect of drugs with anti-inflammatory and anti-apoptotic properties administered to the donor in encephalic death in reducing inflammation of organs to be transplanted. This study aims to evaluate the use of liraglutide in patients with brain death in relation to their ability to attenuate the inflammation induced by encephalic death by means of a randomized clinical trial.
The intervention group will be composed of individuals deceased in brain dead, after the conclusion of the brain dead protocol by the teams responsible for the Intensive care and will receive liraglutide. The control group will be composed of the same population of individuals who died in brain dead of the intervention group, but will receive a placebo.
74 studies on the registry are indexed under Brain Death; 10 are open to participants now.
This study's enrollment of 50 is below the median of 154 across 39 interventional studies indexed under Brain Death.
Browse Brain Death studies →Hospital de Clinicas de Porto Alegre is the lead sponsor of 456 studies on the registry; 61 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
0,5ml
0,5ml
Drug: Liraglutide
liraglutide 3mg 6/6 hours
Also known as: placebo
change inflammation
change interleukin 6
Time frame: from 6 hours to 24 hours
change inflammation with liraglutide
change interleukin 8
Time frame: from 6 to 24 hours
change inflammation liraglutide group
change interleukin 10
Time frame: from 6 to 24 hours
change inflammation intervention group
change tumor necrosis factor-alpha
Time frame: from 6 to 24 hours
change inflammation
change interferon gamma
Time frame: from 6 to 24 hours
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liraglutide
Hospital de Clinicas de Porto Alegre →